title: Maraviroc can improve lipid profiles in dyslipidemic patients with HIV: results from the MERIT trial.
abstract: OBJECTIVE
  We investigated the effects of maraviroc, the first approved CC-chemokine receptor 5 (CCR5) antagonist, on blood lipids in a post hoc analysis of the phase 3 MERIT study in treatment-naïve patients.
  
  
  METHODS
  Patients received maraviroc 300 mg twice daily (n = 360) or efavirenz 600 mg once daily (n = 361), both in combination with zidovudine/lamivudine, for up to 96 weeks. Baseline and on- treatment lipid profiles were analyzed according to National Cholesterol Education Program (NCEP) thresholds.
  
  
  RESULTS
  Baseline characteristics and lipid profiles were comparable between groups. Among patients with total cholesterol (TC) and low-density lipoprotein cholesterol (LDL-c) below NCEP treatment thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded those thresholds at 96 weeks (TC: 35% [74/209] vs 11% [20/188], P < .0001; LDL-c: 23% [47/197] vs 8% [15/183], P < .0001). Among patients exceeding NCEP thresholds at baseline, significantly more efavirenz- than maraviroc-treated patients exceeded the thresholds at 96 weeks (TC: 83% [24/29] vs 50% [17/34], P = .0084; LDL-c: 86% [19/22] vs 55% [16/29], P = .0314). Of those with baseline high- density lipoprotein cholesterol (HDL-c) < 40 mg/dL, 43% (56/130) of maravirocand 62% (86/139) of efavirenz-treated patients achieved HDL-c≥40 mg/dL at 96 weeks (P = .0020).
  
  
  CONCLUSIONS
  Maraviroc was not associated with elevations in TC, LDL-c, or triglycerides and showed beneficial effects on lipid profiles of dyslipidemic patients.
authors.affiliation: Indications Discovery, Pfizer Inc, St. Louis, MO, USA.
authors.forename: A
authors.initials: A
authors.lastname: MacInnes
authors.forename: A
authors.initials: A
authors.lastname: Lazzarin
authors.forename: G
authors.initials: G
authors.lastname: Di Perri
authors.forename: J G
authors.initials: JG
authors.lastname: Sierra-Madero
authors.forename: J
authors.initials: J
authors.lastname: Aberg
authors.forename: J
authors.initials: J
authors.lastname: Heera
authors.forename: N
authors.initials: N
authors.lastname: Rajicic
authors.forename: J
authors.initials: J
authors.lastname: Goodrich
authors.forename: H
authors.initials: H
authors.lastname: Mayer
authors.forename: H
authors.initials: H
authors.lastname: Valdez
mesh_terms: D000328:Adult; D000480:Alkynes; D019380:Anti-HIV Agents / Q000008:administration & dosage*; D048588:Benzoxazines / Q000008:administration & dosage*; D065100:CCR5 Receptor Antagonists; D016009:Chi-Square Distribution; D002784:Cholesterol / Q000097:blood; D003510:Cyclohexanes / Q000008:administration & dosage*; D003521:Cyclopropanes; D050171:Dyslipidemias / Q000097:blood / Q000188:drug therapy* / Q000821:virology*; D005260:Female; D015658:HIV Infections / Q000097:blood* / Q000188:drug therapy / Q000821:virology; D015497:HIV-1 / Q000302:isolation & purification*; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D000077592:Maraviroc; D019713:Receptors, CCR5 / Q000378:metabolism; D014230:Triazoles / Q000008:administration & dosage*; D014280:Triglycerides / Q000097:blood
chemical_list: D000480:Alkynes; D019380:Anti-HIV Agents; D048588:Benzoxazines; D065100:CCR5 Receptor Antagonists; D003510:Cyclohexanes; D003521:Cyclopropanes; D019713:Receptors, CCR5; D014230:Triazoles; D014280:Triglycerides; D002784:Cholesterol; C098320:efavirenz; D000077592:Maraviroc